TIDMERGO

RNS Number : 7548A

Ergomed plc

14 September 2018

PRESS RELEASE

FOR IMMEDIATE RELEASE

Notice of Interim Results

London, UK - 14 September 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, will announce its interim results for the six months ended 30 June 2018 on Wednesday 19(th) September 2018.

Stephen Stamp, Chief Executive Officer and Stuart Jackson, Chief Financial Officer, will host a presentation and conference call for analysts at 8:30am BST on the day of the results at the offices of Numis Securities, The London Stock Exchange Building, 10 Paternoster Square, London, EC4M 7LT.

ENDS

Enquiries:

 
 Ergomed plc                                        Tel: +44 (0) 1483 503 205 
 Stephen Stamp (Chief Executive Officer) 
  Stuart Jackson (Chief Financial Officer) 
 
 Numis Securities Limited                           Tel: +44 (0) 20 7260 1000 
 Michael Meade / Freddie Barnfield (Nominated 
  Adviser) 
 James Black (Joint Broker) 
 
 Consilium Strategic Communications -               Tel: +44 (0) 20 3709 5700 
  for UK enquiries 
 Chris Gardner / Mary-Jane Elliott                ergomed@consilium-comms.com 
  Matthew Neal / Olivia Manser 
 
 MC Services - for Continental European                Tel: +49 211 5292 5222 
  enquiries 
 Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORDBGDCUBBBGIX

(END) Dow Jones Newswires

September 14, 2018 02:01 ET (06:01 GMT)

Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ergomed Charts.
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ergomed Charts.